Inhibition of GBA2 is a side effect of N-butyl-deoxynojirimycin (miglustat), a registered treatment for GBA1-deficient type 1 GD and Niemann–Pick disease type C (NPC) patients. Here, GBA2 is linked to Niemann-Pick disease type C.